Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia, Myeloid, Acute 3Leukemia 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

blinatumomab 3Cytarabine 3venetoclax 2revumenib 2Daunorubicin 2quizartinib 1obinutuzumab 1nilotinib 1ivosidenib 1etoposide phosphate 1bosutinib 1acalabrutinib 1Mitoxantrone 1Midazolam 1Itraconazole 1Imatinib Mesylate 1Idarubicin 1Gemtuzumab 1Etoposide 1Drug Therapy 1Cobicistat 1Azacitidine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Leukemia × venetoclax × Clear all
NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

AbbVie

Phase 3 Completed
211 enrolled 30 charts 1 FDA
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT03836261 2024-12-27

AMPLIFY

Acerta Pharma BV

Phase 3 Active not recruiting
984 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡